The litigation, spearheaded by the Rosen Law Firm, claims Hims & Hers failed to disclose that it shared sensitive consumer health information with third-party advertising platforms. Furthermore, the complaint alleges the company misrepresented its medical consultation process, charging customers for prescriptions almost immediately after they submitted intake forms, rather than waiting for an actual provider assessment as suggested to users. These practices allegedly exposed the firm to significant regulatory scrutiny and potential financial penalties, undermining previous positive statements about the company's operational health.

Investors seeking to participate in this action are not required to pay out-of-pocket fees, as the case proceeds under a contingency arrangement. While the court has not yet certified a class, those interested in serving as lead plaintiff must file their motions by the November 2 deadline. Shareholders who choose not to take this role remain part of the potential class, though they retain the right to select their own legal counsel or opt out of the proceedings entirely.